Company intelligence / Profile preview

Halozyme Therapeutics

Ownership: Private
Development stage: Other

Overview

Halozyme generates substantial royalty revenue from its ENHANZE drug delivery platform, which enables subcutaneous delivery of biologics. The company reported record revenue of $1.015 billion for full year 2024, with royalty revenue increasing 65% year-over-year. Trailing twelve-month revenue reached $1.179 billion.

Modalities: EnzymeBiologicDrug delivery technology
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Halozyme Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Halozyme Therapeutics.

Explore the full profile